News | January 13, 2025

The new Express License service removes barriers to accessing the company's transformative technology for startups.


Jan. 13, 2025 -- ERS Genomics, the CRISPR licensing company, has announced the launch of its Express License platform to provide small research enterprises and startups with affordable and rapid access to the world’s largest foundational and essential CRISPR/Cas9 patent portfolio.

ERS Genomics is committed to providing responsible and effective access to CRISPR/Cas9 technology. To support small and early-stage organizations, ERS now offers a non-exclusive Express License for internal research use, specifically designed for companies with fewer than 15 employees and under $10 million in funding. This streamlined licensing option enables a broader spectrum of innovators to access CRISPR/Cas9 intellectual property in a cost-effective and efficient way, fostering groundbreaking research and development in areas such as synthetic biology, disease modeling, gene editing, high-throughput screening and functional genomics.

Professor Emmanuelle Charpentier, Nobel Prize Winner & ERS Genomics Co-Founder, said, "Our new express license platform represents an exciting step forward in democratizing access to the foundational CRISPR/Cas9 IP. By simplifying the process and making it more affordable, we’re empowering startups and small companies to innovate and bring groundbreaking solutions to the forefront of science and industry."

Candidate organizations can secure an Express License by demonstrating their eligibility through scientific credentials such as research publications, academic collaborations, or technology-related patents. Interested organizations can verify their eligibility and submit their application through ERS' online platform.

John E Milad, CEO, ERS Genomics, said, "Our new Express License platform streamlines and accelerates access to CRISPR/Cas9, making it more affordable than ever for smaller organizations. This initiative represents a major step toward democratizing this Nobel Prize-winning technology, empowering companies of all sizes to harness its transformative potential. We are proud to provide the industry's most accessible and cost-effective solution for accessing foundational CRISPR/Cas9 intellectual property, honoring Prof. Charpentier’s enduring spirit of innovation."

Additional information is available at ERS Express License.

Current licensees include GSK, Merck, Bayer, ThermoFisher Scientific, Corteva, Lonza, Taconic, Danaher, PerkinElmer, Charles River Laboratories, Synthego and Cargill. For additional information please visit www.ersgenomics.com.


Subscribe Now